EBR Systems reported 40 WiSE commercial implants in Q3, down from 46 in Q2 and below its prior forecast, as leadership changes and a sales strategy reset disrupted activity. Higher Medicare reimbursement and progress at its new manufacturing facility offer potential offsets, but both remain dependent on execution and regulatory approval.
- 40 WiSE commercial implants in Q3, down from 46 in Q2
- Preliminary revenue of US$2.43 million to US$2.53 million, versus US$2.6 million in Q2
- September cases fell to about half the July-August average
- CMS increased eligible Medicare inpatient reimbursement from 1 October
- Santa Clara facility received ISO 13485 certification, with FDA approval still pending
Commercial Reset Pushes Q3 Implant Volumes Lower
EBR Systems, Inc. (ASX:EBR) recorded 40 commercial WiSE implants during the September quarter, a sharper test of its US rollout than the company had forecast. The result was down from 46 in Q2, while September cases were about half the average recorded in July and August.
EBR attributed the shortfall to a commercial leadership transition, implementation of a refocused execution strategy and additional field training. Chief executive John McCutcheon has taken direct responsibility for the commercial organisation while the company searches for a new commercial leader, with Michael Sot promoted to Director of US Sales.
The company is now moderating new hospital activations in favour of deeper utilisation within existing accounts, more frequent procedures and improved case scheduling. That change has not yet appeared in the numbers. EBR had 40 activated hospitals at 30 September, including 20 that had completed at least three WiSE implants, while total implants across its pilot and Limited Market Release phases reached 157.
Revenue Slips Ahead of Final Quarterly Accounts
EBR expects preliminary unaudited Q3 revenue of between US$2.43 million and US$2.53 million, compared with US$2.6 million in Q2. The range remains subject to quarter-end closing adjustments and has not been audited or reviewed by the company’s independent accounting firm.
The softer quarter came despite the reimbursement pathway becoming more favourable. CMS finalised higher Medicare inpatient payments for eligible WiSE procedures from 1 October, with base rates rising by approximately 58% and 93% after reassignment to higher-value MS-DRGs. Including the maximum available New Technology Add-on Payment of US$41,145, illustrative total Medicare payments could reach about US$77,839 or US$66,566, depending on the applicable procedure category. Actual payments will vary by hospital, case and NTAP eligibility, leaving the commercial benefit unproven until procedure volumes increase.
Santa Clara Facility Clears Inspection but Approval Remains Open
Operationally, EBR completed the FDA’s pre-approval inspection of its new Santa Clara manufacturing facility and secured ISO 13485 certification during the quarter. The inspection produced two Form 483 observations, both of which EBR said it had promised to correct. The FDA’s final inspection classification and decision on the PMA supplement remain outstanding. The company continues to anticipate approval by the end of 2026, but the inspection itself is not approval. The milestone follows the Santa Clara FDA inspection, which also produced two observations and left the final determination pending.
The expanded site has potential annual capacity of 9,600 systems, which EBR equates to approximately US$607.6 million in revenue. That figure is a capacity estimate rather than a forecast of sales, and its relevance depends first on regulatory clearance, then on hospitals and physicians using the system at a much higher rate.
Capital Raising Funds the Next Execution Test
EBR completed the final tranche of its A$150 million capital raising in August, giving it funding to continue commercial expansion, manufacturing scale-up and its path towards cash flow breakeven. It also launched the single-use WiSE Coupler and trained 10 physicians during the quarter, taking the total number trained to 100.
The immediate question is whether the commercial reset produces the intended repeat activity in Q4. Higher reimbursement, a larger manufacturing footprint and a funded balance sheet improve the platform around WiSE, but none directly resolves the weak September case cadence. EBR expects to provide final quarterly financial and operating data around 10 November, when cash usage and the effect of the reset should become clearer.
Bottom Line?
EBR has improved the reimbursement and manufacturing setup, but Q4 implant frequency will determine whether the commercial reset is repairing momentum or merely explaining its absence.
Questions in the middle?
- Will deeper utilisation within the 40 activated hospitals lift Q4 implants after September’s sharp slowdown?
- When will the FDA reach a final decision on the Santa Clara facility’s PMA supplement?
- How much of the higher Medicare reimbursement will translate into hospital adoption and procedure growth?